# Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

> **NCT01584440** · PHASE2 · COMPLETED · sponsor: **Avanir Pharmaceuticals** · enrollment: 220 (actual)

## Conditions studied

- Agitation
- Alzheimer's Disease

## Interventions

- **DRUG:** AVP-923-20
- **DRUG:** Placebo
- **DRUG:** AVP-923-30

## Key facts

- **NCT ID:** NCT01584440
- **Lead sponsor:** Avanir Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-13
- **Primary completion:** 2014-07-30
- **Final completion:** 2014-07-30
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01584440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01584440, "Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01584440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*